Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : Canada considers what to do with millions of unused COVID-19 vaccine doses

10/22/2021 | 04:21pm EST

OTTAWACanada must decide what to do with millions of unused COVID-19 vaccine doses now that officials have confirmed they won't be needed to vaccinate children.

Roughly 6.6 million doses have been distributed to the provinces but not yet used, and there are an extra 13 million in Canada's central vaccine inventory.

Dr. Theresa Tam, the chief public health officer, says provincial and federal governments are working to figure out how many doses will be needed in Canada so that everyone can be fully vaccinated, and get a booster if they need one.

At the same time, they are keeping tabs on when doses expire to make sure they do not go to waste.

"Vaccines are a valuable commodity and extremely important to Canada, but also the world," Tam said at a briefing Friday.

Canada has already announced it would donate more than 40 million doses to COVAX, a global vaccine-sharing alliance, to be distributed to countries in need.

Those donations focused on the Johnson & Johnson and Oxford-AstraZeneca vaccines. Though both are approved by Health Canada, Canada's domestic vaccine strategy focuses on administering mRNA vaccines from Pfizer-BioNTech and Moderna.

With 2.9 million pediatric doses of the Pfizer-BioNTech vaccine set to be delivered to Canada for kids aged five to 11, it's likely Canada won't use all of its mRNA vaccines before they expire.

Initial agreements between Canada and the mRNA manufacturers didn't allow for those doses to be donated, but that has been worked out, Tam said.

"There are ways that we can donate this vaccine now," Tam said.

Arrangements have been made between the government, the vaccine manufacturers and COVAX, the global vaccine sharing initiative, to donate doses that can't be used or stored.

Health Canada is also looking at the possibility of extending the shelf life of some vaccines based on new data from the manufacturers, so they can be kept in storage for a few extra months.

"As we know more about the vaccines, and also as manufacturers make changes to their formulations, we get more information about how stable these vaccines are, how long they can be held on the shelf," said Dr. Supriya Sharma, chief medical adviser at Health Canada.

Moderna has already made a submission to extend the shelf life of existing vaccines in Canada from seven months to 10 months, for example.

Sharma said any changes to the shelf life of vaccine products would have to be approved by Health Canada and supported by data on the safety and efficacy of the longer expiry.

This report by The Canadian Press was first published Oct. 22, 2021.

© 2021 The Canadian Press. All rights reserved., source Canadian Press DataFile

All news about MODERNA, INC.
04:34aWith new Omicron case detected, UK awaits COVID booster advice
RE
11/26Vaccine companies testing efficacy against COVID-19 Omicron variant
AQ
11/26Moderna to Test Variant-Specific Vaccine Candidate
DJ
11/26Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
BU
11/26ADRs Close Lower; BioNTech Rises, Carnival Drops
DJ
11/26US Stocks, Treasury Yields Sink With Crude Oil as Concern Mounts Over New COVID-19 Stra..
MT
11/26CLOSE UPDATE : US Stocks, Treasury Yields Sink With Crude Oil as Concern Mounts Over New C..
MT
11/26Delta, Carnival fall; Moderna, Clorox rise
AQ
11/26Stocks tumble on new coronavirus variant fear
RE
11/26Covid-19 Vaccine Maker Stocks Higher Amid Variant Concerns
DJ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 449 M - -
Net income 2021 11 170 M - -
Net cash 2021 12 747 M - -
P/E ratio 2021 12,5x
Yield 2021 -
Capitalization 134 B 134 B -
EV / Sales 2021 6,93x
EV / Sales 2022 5,38x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Last Close Price 329,63 $
Average target price 272,53 $
Spread / Average Target -17,3%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431
ALNYLAM PHARMACEUTICALS, INC.45.06%22 548